212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
A.J. Wagner, S. Yazji, J.A. Morgan, E. Choy, S. George, M. Hohos, M. O'Mara, G.D. DemetriVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72144-x
File:
PDF, 59 KB
english, 2008